http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Daisuke Takahari,Keitaro Shimozaki,Izuma Nakayama,Kengo Nagashima,Koichiro Yoshino,Koshiro Fukuda,Shota Fukuoka,Hiroki Osumi,Mariko Ogura,Takeru Wakatsuki,Akira Ooki,Eiji Shinozaki,Keisho Chin,Kensei 대한위암학회 2023 Journal of gastric cancer Vol.23 No.4
Purpose: Determination of optimal treatment strategies for HER2-positive advanced gastric cancer (AGC) in randomized trials is necessary despite difficulties in direct comparison between trastuzumab deruxtecan (T-DXd) and nivolumab as third or later-line treatments. Materials and Methods: This single-institution, retrospective study aimed to describe the real-world efficacy and safety of T-DXd and nivolumab as ≥ third line treatments for HER2-positive AGC between March 2016 and May 2022. Overall, 58 patients (median age, 64 years; 69% male) were eligible for the study (T-DXd group, n=20; nivolumab group, n=38). Results: Most patients exhibited a HER2 3+ status (72%) and presented metastatic disease at diagnosis (66%). The response rates of 41 patients with measurable lesions in the T-DXd and nivolumab groups were 50% and 15%, respectively. The T-DXd and nivolumab groups had a median progression-free survival of 4.8 months (95% confidence interval [CI], 3.3, 7.0) and 2.3 months (95% CI, 1.5, 3.5), median overall survival (OS) of 10.8 months (95% CI, 6.9, 23.8) and 11.7 months (95% CI, 7.6, 17.1), and grade 3 or greater adverse event rates of 50% and 2%, respectively. Overall, 64% patients received subsequent treatment. Among 23 patients who received both regimens, the T-DXd–nivolumab and nivolumab–T-DXd groups had a median OS of 14.0 months (95% CI, 5.0, not reached) and 19.3 months (95% CI, 9.5, 25.1), respectively. Conclusions: T-DXd and nivolumab showed distinct efficacy and toxicity profiles as ≥ third line treatments for HER2-positive AGC. Considering the distinct features of each regimen, they may help clinicians personalize optimal treatment approaches for these patients.
Sou N. Matsunaga,Kojiro Shimada,Tatsuhiko Masuda,Junya Hoshi,Sumito Sato,Hiroki Nagashima,Hiroyuki Ueno 한국대기환경학회 2017 Asian Journal of Atmospheric Environment (AJAE) Vol.11 No.1
Ozone concentration in Tokyo Metropolitan area is one of the most serious issues of the local air quality. Tropospheric ozone is formed by radical reaction including volatile organic compound (VOC) and nitrogen oxides (NOx). Reduction of the emission of reactive VOC is a key to reducing ozone concentrations. VOC is emitted from anthropogenic sources and also from vegetation (biogenic VOC or BVOC). BVOC also forms ozone through NOx and radical reactions. Especially, in urban area, the BVOC is emitted into the atmosphere with high NOx concentration. Therefore, trees bordering streets and green spaces in urban area may contribute to tropospheric ozone. On the other hand, not all trees emit BVOC which will produce ozone locally. In this study, BVOC emissions have been investigated (terpenoids: isoprene, monoterpenes, sesquiterpenes) for 29 tree species. Eleven in the 29 species were tree species that did not emit BVOCs. Three in 12 cultivars for future planting (25 %) were found to emit no terpenoid BVOCs. Eight in 17 commonly planted trees (47%) were found to emit no terpenoid BVOC. Lower-emitting species have many advantages for urban planting. Therefore, further investigation is required to find the species which do not emit terpenoid BVOC. Emission of reactive BVOC should be added into guideline for the urban planting to prevent the creation of sources of ozone. It is desirable that species with no reactive BVOC emission are planted along urban streets and green areas in urban areas, such as Tokyo.